drugset / Trial / NCT02703571

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

NCT02703571

Phase 1 Terminated 95 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Phase Ib dose escalation in advanced solid tumors to identify dose for Phase II dose expansion in advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer. Open-label, nonrandomized.

Timeline

Start
2016-06-29
Primary completion
2019-09-24
Completion
2019-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribociclib Small molecule
Subject Trametinib Small molecule

Indications